Clinical Trials Logo

Genital Wart clinical trials

View clinical trials related to Genital Wart.

Filter by:

NCT ID: NCT04422366 Recruiting - Cervical Cancer Clinical Trials

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: April 28, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .

NCT ID: NCT04073082 Active, not recruiting - Clinical trials for Hidradenitis Suppurativa

Safety and Efficacy of Laser Therapy in Gynaecology

Start date: July 24, 2019
Phase:
Study type: Observational

The aim of this study is to retrospectively evaluate the effectiveness and safety of Er:YAG laser for treatment of different gynecological indication, e.g. genital lesions, Bartholin's cyst, condyloma, episiotomy scars, lesions of hydradenitis suppurativa and use of laser in genital surgery used in private practice.

NCT ID: NCT03676101 Completed - Vulvar Cancer Clinical Trials

Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: October 10, 2018
Phase: Phase 1
Study type: Interventional

To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.

NCT ID: NCT03153566 Not yet recruiting - Genital Wart Clinical Trials

Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients

Start date: June 1, 2017
Phase: Phase 3
Study type: Interventional

Cutaneous and genital warts are common dermatological conditions caused by Human Papilloma Virus. Although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several years, most patients seek treatment because the warts are unsightly and often tender or painful.

NCT ID: NCT00999986 Completed - Genital Wart Clinical Trials

Low Dose Cyclophosphamide Treats Genital Warts

Start date: January 2007
Phase: Phase 3
Study type: Interventional

Condylomata acuminata (CA) caused by human papillomavirus (HPV) is a common sexually transmitted disease with half a million new cases diagnosed in the United States per year. Recurrence is a major challenge for CA treatment. The investigators have demonstrated that FOXP3+ regulatory T (Treg) cells mediate the immunosuppression in large genital warts. And low-dose cyclophosphamide (CY), a conventional chemotherapy drug, has been reported to selectively deplete Treg cells in cancer patients. Therefore, the investigators hypothesized that low-dose CY can be used to treat genital warts. In this study, 104 CA patients have been recruited for clinical trial with a 1:2 randomization. Among them, 64 patients received low-dose cyclophosphamide and 32 received placebo. In 8 extra patients, high-dose cyclophosphamide was given.